FDA Approves Liposomal Amikacin Inhalation Suspension for Bacterial Lung Disease
September 29th 2018The US Food and Drug Administration has approved Arikayce for the treatment of lung disease caused by Mycobacterium avium complex (MAC) bacteria in a limited population of patients who do not respond to conventional treatment.